Evidence map›Paper›PMID 42229634›Full record

ArticleJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2026

SARS-CoV-2 mRNA Vaccination Improved Survival in NSCLC Treated With Radiotherapy.

Xinyan Xu, Maliazurina B Saad, Adam Grippin, Hui Xu, Amgad Muneer, Elliana Young, Steven H Lin, Zhongxing Liao, Saumil Gandhi, Peter Balter and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Xinyan XuDepartment of Thoracic Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Maliazurina B SaadDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Adam GrippinDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Hui XuDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Amgad MuneerDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Elliana YoungDepartment of Enterprise Data Engineering & Analytics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Steven H LinDepartment of Thoracic Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Zhongxing LiaoDepartment of Thoracic Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Saumil GandhiDepartment of Thoracic Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Peter BalterDepartment of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Matthew Stephen NingDepartment of Thoracic Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
David QianDepartment of Thoracic Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Julianna K BronkDepartment of Thoracic Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Aileen ChenDepartment of Thoracic Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Michael O'ReillyDepartment of Thoracic Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Quynh-Nhu NguyenDepartment of Thoracic Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
James WelshDepartment of Thoracic Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Julianne M Pollard-LarkinDepartment of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
John V HeymachDepartment of Thoracic-Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
J Jack LeeDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jia WuDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Thoracic-Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Joe Y ChangDepartment of Thoracic Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: jychang@mdanderson.org.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
U OF TEXAS HLTH SCI CTR HOUSTON CENTER FOR CLINICAL AND TRANSLATIONAL SCIENCESUL1RR024148 · NCRR · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MCPHERSON, DAVID D · 2006 to 2010
$27.9M
Radioimmunogenomic Habitat Phenotypes to Predict Efficacy of Neoadjuvant Immunotherapies in Non-Small Cell Lung CancerR01CA262425 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CASCONE, TINA, WU, JIA · 2021 to 2025
$3.2M
Integrated blood and radiomic subtyping to guide immunotherapy treatment selection and early response assessment in metastatic non-small cell lung cancerR01CA276178 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Natalie Vokes, Jia Wu · 2023 to 2026
$2.6M
NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA262425NCI NIH HHS R01 CA276178NCRR NIH HHS UL1 RR024148
6 · The paper itself

Abstract

Stereotactic ablative radiotherapy (SABR) is standard for early stage NSCLC, but strategies to enhance its systemic antitumor immune effects remain limited. Preclinical data suggest that severe acute respiratory syndrome coronavirus 2 mRNA vaccines enhance innate immunity and antigen presentation, raising the possibility that vaccination could augment radiotherapy-induced immune priming. We evaluated the clinical impact of peri-SABR vaccination (defined as within 3 mo before or after SABR) in 413 real-world patients with T1 to 3N0M0 NSCLC who were treated during the pandemic era, including 144 patients who received vaccination within this window. In time-varying analyses, vaccination was associated with improved recurrence-free survival (hazard ratio [HR] = 0.69, 95% confidence interval [CI]: 0.49-0.98, p = 0.039) and a trend toward improved overall survival (HR = 0.66, 95% CI: 0.42-1.03, p = 0.069). In propensity score-matched time-dependent analyses, vaccination remained associated with improved recurrence-free survival (HR = 0.61, 95% CI: 0.40-0.91, p = 0.016) and overall survival (HR = 0.57, 95% CI: 0.34-0.94, p = 0.029), with directionally consistent findings observed after multivariable adjustment. These findings support further investigation into potential interactions between severe acute respiratory syndrome coronavirus 2 mRNA vaccination and SABR-induced antitumor immunity.

Indexed as

Carcinoma, Non-Small-Cell LungCOVID-19COVID-19 VaccinesLung NeoplasmsRadiosurgerySARS-CoV-2AgedAged, 80 and overFemaleHumansMaleMiddle AgedSurvival RateCOVID-19 VaccinesAntitumor immunityNon–small cell lung cancerRecurrence-free survivalSARS-CoV-2 vaccinationStereotactic ablative radiotherapy

Identifiers

PMID42229634
PMCPMC13348152

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.